

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/974,653	9/974,653 10/10/2001		Andrew D. Bicek	760-49	9912
7590 06/15/2004			EXAMINER		
Ludomir A. B			NGUYEN, VI X		
HOFFMANN & 6900 Jericho T			ART UNIT	PAPER NUMBER	
Syosset, NY			3731		

DATE MAILED: 06/15/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applicatio	n No.	Applicant(s)					
		09/974,65	3	BICEK ET AL.					
	Office Action Summary	Examiner	-	Art Unit					
		Victor X No		3731					
7 Period for F	he MAILING DATE of this communication Reply	appears on the	cover sheet with the c	orrespondence ad	Idress				
THE MA - Extension after SIX - If the peri - If NO per - Failure to Any reply	TENED STATUTORY PERIOD FOR RE ILING DATE OF THIS COMMUNICATIO as of time may be available under the provisions of 37 CFR (6) MONTHS from the mailing date of this communication. od for reply specified above is less than thirty (30) days, a iod for reply is specified above, the maximum statutory per reply within the set or extended period for reply will, by state received by the Office later than three months after the material term adjustment. See 37 CFR 1.704(b).	N. t 1.136(a). In no eve reply within the statu iod will apply and wil atute, cause the appli	nt, however, may a reply be tim tory minimum of thirty (30) days expire SIX (6) MONTHS from cation to become ABANDONEI	nely filed s will be considered time the mailing date of this c O (35 U.S.C. § 133).	ty. xommunication.				
Status									
1)⊠ R€	esponsive to communication(s) filed on 30	0 March 2004.							
	★ This action is FINAL. 2b)  This action is non-final.								
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Disposition	of Claims								
4a 5)	aim(s) 17-24 and 39 is/are pending in the ) Of the above claim(s) is/are without aim(s) is/are allowed. aim(s) 17-24 and 39 is/are rejected. aim(s) is/are objected to. aim(s) are subject to restriction and	drawn from cor							
Application	Papers								
9)∐ Th	e specification is objected to by the Exam	niner.							
	10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.								
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
R∈ 11)∐ Th	eplacement drawing sheet(s) including the cor e oath or declaration is objected to by the	e Examiner. No	te the attached Office	Action or form P	TO-152.				
Priority und	der 35 U.S.C. § 119								
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>									
2) Notice of 3) Information	) If References Cited (PTO-892) If Draftsperson's Patent Drawing Review (PTO-948) Ition Disclosure Statement(s) (PTO-1449 or PTO/SE o(s)/Mail Date		4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:		ГО-152)				

#### **DETAILED ACTION**

### Election/Restrictions

1. This application contains claims 1-16,25-27 and 28-38 drawn to non-elected inventions. In December 2, 2003, applicant elected to prosecute Species II of Group III that associated with fig. 5 without traverse. Furthermore, Applicant has stated that all claims 17-27 read upon the elected species. However, claims 1-16,25-27 and 28-38 do not read upon the elected species. Therefore, non-elected claims 1-16,25-27 and 28-38 are withdrawn from further consideration.

The requirement is deemed proper and is therefore made Final.

## Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 17-24 are rejected under 35 U.S.C. 102 (e) as being anticipated by Davila et al (U.S. 6,296,661).

Regarding claims 17-20 and 39, Davila et al disclose in figs 6-9, a stent graft for insertion into target site within a vessel of a patient, including: a main stent (80) has a radially-expandable body, at least one support stent (60), and a sheath (104) between the body, and the support stent where no portions of the main stent are in contact with the support stent, and the sheath is not bonded to the support stent. Note that the support stent (60) is capable of producing a force with the stent to hold the sheath (104) in place. The statement of intended use and other functional

Application/Control Number: 09/974,653

Art Unit: 3731

statements have been carefully considered but are deemed not to impose any structural limitations on the claims distinguishable over Davila et al which is capable of being used as claimed if one desires to do so.

Regarding claims 18-20, Davila et al disclose the support stent (60) is superelastic alloys (see col. 5, lines24-32). The sheath (104) disposes radially outwardly or inwardly of the stent.

Regarding claims 21-22, Davila et al disclose the support stent has an axial length which is less than the axial length of the body (fig. 6, see col. 5, lines 21-25).

Regarding claims 23-24, Davila et al disclose sheath is selected from the group consisting of a polymeric/a biomaterial sleeve (see col. 9, lines 25-38). The sheath is also treated with a drug selected from the group consisting of biocompatible material (see col. 3, lines4-25).

## Response to Arguments

3. Applicant's arguments filed 3/30/2004 have been fully considered but they are not persuasive. With respect to claim 17, the examiner disagrees with applicant's remarks that there is no disclosure in Davila et al to rely on any pressing force generated by the inner and outer stents to hold the graft in place. As the examiner has pointed out above, Davila et al disclose in figs 6-9, a stent graft for insertion into target site within a vessel of a patient, including: a main stent (80) has a radially-expandable body, where at least one support stent (60) and a sheath (104) come between the body. The support stent with no portions of the main stent are in contact with the support stent. Note that the support stent (60, best view in figs. 6 and 9e) is capable of producing a force with the stent to hold the sheath (104) in place. The statement of intended use and other functional statements have been carefully considered but are deemed not to impose any structural limitations on the claims distinguishable over Davila et al which is capable of being

Application/Control Number: 09/974,653

Art Unit: 3731

used as claimed if one desires to do so. Therefore, at least claim 17 of the invention is not defined over the Davila et al '661 reference.

#### Conclusion

4. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Victor X Nguyen whose telephone number is (703) 305-4898. The examiner can normally be reached on M-F (8-4.30 P.M).

The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 09/974,653 Page 5

Art Unit: 3731

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Victor X Nguyen Examiner Art Unit 3731

Vn  $\sqrt{\nu}$ June 11, 2004

JULIAN W. WOO
PRIMARY EXAMINER

Julian M. Moo